Anat Ashkenazi, Eli Lilly CFO
September 14, 2022 01:33 PM EDT
Pharma
Marketing

Is Lil­ly plan­ning two brands for tirzepatide? CFO dis­cuss­es di­a­betes and obe­si­ty pos­si­bil­i­ties

Beth Snyder Bulik

Senior Editor

Eli Lil­ly is ad­dress­ing the pos­si­bil­i­ty of two brand names for tirzepatide — again. The drug — which is al­ready ap­proved to treat type 2 di­a­betes as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times